Lenalidomide Stragen

Lenalidomide, the active ingredient in Lenalidomide Stragen, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is employed in the treatment of certain hematologic malignancies, specifically multiple myeloma and myelodysplastic syndromes, in adult patients.

GNH USA supplies Lenalidomide Stragen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets and providing reliable logistics for timely delivery.

Lenalidomide is used in hematologic oncology to target malignant plasma cells and dysplastic bone‑marrow clones.

Multiple Myeloma: improves progression‑free and overall survival in patients with relapsed or refractory disease. Myelodysplastic Syndromes: reduces transfusion dependence and delays progression to acute leukemia. Myelodysplastic Syndrome with del(5q) deletion: corrects anemia and decreases need for red‑cell support.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels leading to easy bruising. - Anemia: decreased red blood cells causing weakness. - Diarrhea: loose stools that may require hydration. - Rash: skin irritation or redness.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: profound infection susceptibility. - Severe thrombocytopenia: risk of serious bleeding. - Secondary primary malignancies: emergence of new cancers. - Severe liver injury: marked elevation of hepatic enzymes. - Hypersensitivity reactions: including anaphylaxis.

Before initiating therapy, clinicians should evaluate specific safety considerations.

Pregnancy Contraindication: Lenalidomide is teratogenic and must not be used during pregnancy. Thrombosis Risk: Assess patient history and consider prophylactic anticoagulation when appropriate. Blood Count Monitoring: Perform regular CBCs to detect cytopenias early. Renal Impairment: Adjust dosing in patients with reduced kidney function. Hepatic Impairment: Use caution in severe liver disease. Store at ambient temperature: keep in the original container, protect from moisture and light.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - NSAIDs: additive risk of gastrointestinal bleeding. - CYP3A4 substrates (e.g., midazolam): may require dose adjustment.